Endotoxin binding and neutralizing protein and uses thereof

Details Endotoxin binding and neutralizing protein and uses thereof Endotoxin binding and neutralizing protein and uses thereof

1997-05-01

2002-05-07

Tsang, Cecilia J. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Separation or purification

C530S414000, C530S416000, C530S422000, C530S857000

Reexamination Certificate

active

06384200

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to pharmaceutical compositions and uses of an endotoxin binding
eutralizing protein which may be isolated from a horseshoe crab. The invention covers, inter alia, pharmaceutical compositions and pharmaceutical uses of the protein, a method of purifying the protein, and an assay for endotoxin based on this protein.
2. Discussion of the Background
Despite aggressive management, septic shock arising from gram-negative sepsis continues to be a leading cause of death in both surgical and medical patients. Death in such patients usually results from cardiovascular collapse and/or multiple organ system failure. One of the main components of gram-negative bacteria thought to play an integral role in causing septic shock is an outer wall constituent, endotoxin.
Endotoxins are high molecular weight complexes, associated with the outer membrane of gram-negative bacteria, that produce pyrogenic reactions upon intravenous administration. Endotoxin is shed from living bacteria and is also released into the environment when bacteria die and decompose. Since gram-negative bacteria are found in great numbers in air, water, and soil, bacterial endotoxin commonly contaminates raw materials and processing equipment used in the manufacturing of, for example, pharmaceuticals.
Bacterial endotoxin is a complex consisting of lipid, carbohydrate and protein. It is characterized by an overall negative charge, heat stability and high molecular weight. Highly purified endotoxin does not contain protein, and is a lipopolysaccharide (LPS). Depyrogenation can generally be achieved by inactivating or removing endotoxin, depending upon the physicochemical nature of the LPS. LPS consists of three distinct chemical regions, lipid A, which is the innermost region, an intermediate core polysaccharide, and an outermost O-specific polysaccharide side chain which is responsible for an endotoxin's particular immunospecificity.
Bacterial endotoxins are known to have profound biological effects in animals and humans, and to cause severe medical problems when present. Symptoms include induction of high fever, activation of complement, and hypotension. It is critical to avoid endotoxin contamination in any pharmaceutical product or medical device which comes into contact with body fluids. High endotoxin levels in sera due to bacterial diseases, such as septicemia, are not easily treated. Antibiotic treatment of the infection only kills the bacteria, leaving the endotoxin from their cell walls free to cause fever.
The horseshoe crab
Limulus polyphemus
is particularly sensitive to endotoxin. The cells from their hemolymph (amebocytes) undergo a complex series of biochemical reactions resulting in clot formation, analogous to mammalian blood coagulation. This phenomenon has been exploited in the form of bioassays sensitive to very low endotoxin levels. Currently, a bioassay of this type is the method of choice for monitoring pharmaceutical manufacturing and is termed Limulus Amebocyte Lysate (LAL). See U.S. Pat. Nos. 4,276,050, 4,273,557, 4,221,866, 4,201,865, 4,038,147, 3,944,391 and 3,915,805, each of which is incorporated herein by reference.
It has long been observed that once endotoxin interacts with LAL the toxin is not recoverable from the clot. See Nachum et al, Journal of Invertebrate Pathology, 32:51-58 (1978). This observation led investigators to postulate two alternative explanations. Either the endotoxin is enzymatically degraded during clot formation or it is bound by some factor causing it to lose toxicity. The present inventors initiated experiments to extract the endotoxin inactivating factor from the LAL.
Other research groups have experimented with endotoxin binding proteins, also referred to as anti-LPS factor. To the inventor's knowledge, the following publications resulting from work in this area are the most relevant to this invention:
Tanaka et al, Biochem. Biophys. Res. Comm. 105, 717-723 (1982),
Iwanaga et al, International symposium on Pyrogen, 84-84 (Jun. 23-26, 1987),
Aketagawa et al, J. Biol. Chem. 261, 7354-7365 (1986),
Hao, U.S. Pat. No. 4,677,194 (Jun. 30, 1987), and
Nachum et al, J. Inv. Path. 32, 51-58 (11978).
Tanaka et al, Iwanaga et al, and Aketagawa et al each conducted research on an anti-LPS factor or endotoxin binding protein isolated from a horseshoe crab system. Based on experimental work done in the inventors' laboratory, it appears that a protein involved in the present invention is the same as that isolated by Iwanaga et al and Tanaka et al. However, these publications do not say anything about pharmaceutical utility of the endotoxin binding
eutralizing protein, and it is difficult to predict in vivo activity based on in vitro experimentation. In fact, neither of these references suggests a practical utility for the anti-LPS factor, and in view of the unpredictable nature of in vivo activity, it has previously not been appreciated that the endotoxin binding
eutralizing protein could be used in a pharmaceutical composition. Furthermore, none of the references disclose the use of the endotoxin binding
eutralizing protein for an endotoxin assay, as disclosed in the present invention. It is notable that the present inventors have also discovered certain endotoxin binding
eutralizing protein variants which have amino acid structures that are different from the anti-LPS factor disclosed in the above-described publications.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide pharmaceutical compositions containing therein an endotoxin-binding
eutralizing protein isolated from a horseshoe crab, which compositions are capable of binding and neutralizing endotoxin in vivo.
It is yet another object of this invention to provide pharmaceutical compositions capable of binding and neutralizing endotoxin in vivo and containing therein an endotoxin binding
eutralizing protein corresponding at least to part of the endotoxin binding and neutralizing domain of the endotoxin binding
eutralizing protein isolated from a horseshoe crab in accordance with the invention.
It is yet another object of the present invention to provide a method for reducing endotoxin concentration and/or neutralizing endotoxin activity in vivo.
It is yet another object of the present invention to provide a method for purifying an endotoxin binding
eutralizing protein from a horseshoe crab.
It is yet another object of the present invention to provide a method of assaying for endotoxin in a fluid.
These and other objects of the present invention which will hereinafter become more readily apparent, have been provided by purifying an endotoxin binding
eutralizing protein from the horseshoe crab
Limulus polyphemus
, and discovering that it has the capability of binding to and neutralizing endotoxin in vivo. It has also been recognized that this purified endotoxin binding
eutralizing protein is useful in an assay for endotoxin. The present inventors have also discovered that there are certain structural variants of the
Limulus polyphemus
endotoxin binding
eutralizing protein, and it is expected that these materials will also possess endotoxin binding
eutralizing ability such that they may be used in the other aspects of the present invention as well.
The present inventors have also discovered a domain within the endotoxin binding protein which is necessary for endotoxin binding
eutralizing. The present invention thus uses a protein corresponding at least to this endotoxin binding
eutralizing domain and up to the complete protein sequence.


REFERENCES:
patent: 3944391 (1976-03-01), Harris et al.
patent: 4107077 (1978-08-01), Sullivan, Jr. et al.
patent: 4188264 (1980-02-01), Iwanaga et al.
patent: 4273557 (1981-06-01), Juranas
patent: 4357142 (1982-11-01), Schall, Jr. et al.
patent: 4652639 (1987-03-01), Stabinsky
patent: 4713347 (1987-12-01), Mitchell et al.
patent: 4758655 (1988-07-01), Houghten
patent: 4780529 (1988-10-01), Hao
patent: 4906567 (1990-03-01), Connelly
pat

Affiliated with

Also associated with

Rating

Endotoxin binding and neutralizing protein and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endotoxin binding and neutralizing protein and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endotoxin binding and neutralizing protein and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2898027